Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Tongue Neoplasms × Erlotinib Hydrochloride × Clear all

Phase

Status

Sponsor Class

OTHER 2 NIH 2 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 2 Neoplasm Metastasis 2 Lung Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Tongue Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Head and Neck Neoplasms 1 EGFR Positive Non-small Cell Lung Cancer 1 Colorectal Neoplasms 1

Interventions

Observation 1 Moxibustion 1 Induction Chemotherapy 1 Erlotinib Hydrochloride 1 DMAC2L protein, human 1 Celecoxib 1 Acupuncture Therapy 1 26S proteasome non-ATPase regulatory subunit 13 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02748707 2022-04-28

ERLO-XIB

Tata Memorial Hospital

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡